Strategic Growth Pillars: The leadership detailed a three-pillar roadmap: (1) A 1 million R&D investment to pioneer AI therapies addressing unmet needs; (2) A targeted 5–10 million biotech acquisition by July 2027 to broaden the pipeline; and (3) Uplisting to OTCQB by Q1 2026 and NASDAQ thereafter to boost liquidity and investor access. Unwavering Management Alignment: The team emphasized their $350,000 personal investment and salary deferral until reaching a$50 million valuation, aligning incentives wit ...